Azenta, Inc. (AZTA) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals: strong cash flow improvement and record Multiomics revenue are positives, but declining gross margins and unclear EPS guidance are concerns. The Q&A highlighted growth challenges due to macroeconomic factors and government funding issues, yet management's optimism for H2 growth and strategic investments provide some reassurance. With a market cap of $2.8 billion, the stock's reaction is likely to be moderate, hence a neutral prediction.
Key Financial Performance
Fourth Quarter Revenue $159 million, up 6% year-over-year on a reported basis, and up 4% organically. Growth driven by Multiomics delivering a record quarter.
Fiscal Year 2025 Revenue $594 million, up 4% on a reported basis, and up 3% organic. Growth supported by strong performance in Next Generation Sequencing, Clinical Biostores, Sample Repository Solutions, and Consumables and Instruments.
Non-GAAP EPS (Fourth Quarter) $0.21, reflecting operational turnaround and disciplined cost execution.
Non-GAAP EPS (Full Year) $0.51, reflecting operational turnaround and disciplined cost execution.
Adjusted EBITDA Margin (Fourth Quarter) 13%, representing expansion of approximately 230 basis points year-over-year. Improvement due to leverage from cost actions and operational performance.
Adjusted EBITDA Margin (Full Year) 11.2%, representing expansion of 310 basis points year-over-year. Improvement due to operational turnaround and disciplined cost execution.
Free Cash Flow (Fourth Quarter) Usage of $6 million, driven by timing of revenue and project-related milestone billing.
Free Cash Flow (Full Year) $38 million, a notable improvement of $26 million year-over-year, driven by improvements in working capital.
Cash, Cash Equivalents, and Marketable Securities $546 million, providing financial flexibility for growth initiatives and shareholder value.
Sample Management Solutions (SMS) Revenue (Fourth Quarter) $86 million, up 2% reported and flat organically. Growth in Automated Stores and Sample Storage offset by softness in Cryogenic Stores.
Multiomics Revenue (Fourth Quarter) $73 million, the highest ever for the segment, representing 11% growth on a reported basis and 10% organic growth. Driven by Next Generation Sequencing and large deals in Europe.
Multiomics Non-GAAP Gross Margin (Fourth Quarter) 43.7%, down 260 basis points year-over-year. Decline driven by product mix and lower volume in Sanger Sequencing and Gene Synthesis.
SMS Non-GAAP Gross Margin (Fourth Quarter) 49.3%, up 180 basis points year-over-year. Improvement due to favorable product mix and improved operational execution and cost management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Next Generation Sequencing: Achieved strong performance with sequencing volume rising 50% year-over-year, contributing to record revenue in the Multiomics segment.
Plasmid-EZ: Revenue growth remains strong, offsetting declines in traditional Sanger Sequencing.
Geographic Expansion: Strong performance in Europe with large deals contributing to record revenue; China posted 17% organic growth despite macro and geopolitical headwinds.
Azenta Business System (ABS): Implemented lean principles, daily management routines, and structured problem solving, leading to measurable improvements in quality, on-time delivery, and productivity.
Operational Efficiencies: Achieved adjusted EBITDA margin expansion of 310 basis points for fiscal 2025, driven by cost management and operational improvements.
Reshaped Commercial Organization: Implemented new leadership, expanded field presence, and sharpened go-to-market targeting to better serve customers and accelerate growth.
Capital Deployment: Maintained $546 million in cash and marketable securities, enabling investments in growth initiatives, share repurchases, and targeted M&A.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Macroeconomic Uncertainty: The company faces ongoing macroeconomic uncertainty, which has led to delayed customer capital expenditure decisions and softer academic and NIH funding. This could impact revenue growth and operational planning.
Geopolitical Uncertainty: Ongoing geopolitical challenges, particularly in regions like China, could disrupt operations and customer demand, despite current resilience in the region.
Customer Budget Constraints: Slower bookings in Cryogenic Stores and delays in capital expenditure decisions by customers due to budget constraints are affecting revenue in the Sample Management Solutions segment.
Shifting Biopharma Priorities: Changes in biopharma priorities could lead to reprioritization of projects and remapping of pipelines, potentially impacting demand for certain services.
Product Mix and Volume Declines: Declines in Sanger Sequencing and Gene Synthesis volumes, along with unfavorable product mix, have negatively impacted gross margins in the Multiomics segment.
Capital Spending Uncertainty: Uncertainty around customer capital spending is expected to result in a slower start to fiscal 2026, with revenue anticipated to decline in the first quarter.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Core Revenue Growth: Anticipated to grow between 3% to 5% in fiscal 2026.
Adjusted EBITDA Margin Expansion: Targeting approximately 300 basis points of year-over-year expansion in fiscal 2026.
Free Cash Flow Generation: Expected to improve by over 30% year-over-year in fiscal 2026.
Segment Growth: Multiomics is expected to deliver low single-digit growth, while Sample Management Solutions is expected to contribute mid-single-digit growth in fiscal 2026.
First Half vs. Second Half Performance: First half of fiscal 2026 expected to see a slower start with revenue declining approximately 1% to 2% year-over-year, while the second half is anticipated to accelerate as commercial investments and growth initiatives gain traction.
Capital Allocation: Plans to maintain a disciplined capital allocation framework, with investments in automation, capacity expansion, and technology to support scalable growth.
Investor Day: Azenta will outline its multiyear growth strategy, long-term financial framework, and capital deployment priorities in December 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividends: No specific mention of a dividend program or payouts was made during the call.
Share Repurchase: The company highlighted its commitment to returning capital to shareholders through share repurchases as one of its four strategic levers for capital deployment. However, no specific details or figures regarding the share repurchase program were provided.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the company's guidance for growth and the factors affecting it?
A:The company expects 3% to 5% growth, with the market growing at 1% to 2%. Factors affecting growth include a slowdown in capital expenditures, particularly in the U.S., and the impact of the government shutdown, which paused grant reviews and approvals. The macro slowdown on CapEx accounts for about 2/3 of the negative growth, while government funding issues account for about 1/3.
Q:What is the update on SMS growth and SRS expectations for the year?
A:SMS is expected to grow mid-single digits, supported by reinvestments in commercial operations and new leadership. SRS is expected to see robust growth due to a new commercial engine, price optimization initiatives, and recent big deals in manufactured and bulk compounds.
Q:What is the current customer base performance across various segments?
A:Pharma is showing strength with spending and project clarity. Biotech is holding tight on CapEx but showing some optimization investments. Academic and government spending slowed due to the government shutdown. Multiomics is seeing normalization in NGS with mid-single-digit growth expected.
Q:What are the expectations for Multiomics and NGS growth?
A:Multiomics is expected to grow in the low single digits, with NGS normalizing to mid-single-digit growth after a prior year of price challenges and volume increases.
Q:What is the framework for SMS growth and price optimization?
A:SMS growth is expected to pick up in the second half of the year, with price optimization contributing in areas like C&I and SRS. The company has streamlined processes to deploy contracted price adjustments effectively.
Q:How is the company restructuring its operations to improve decision-making?
A:The company is moving from a centralized to a decentralized model, aligning general managers and product managers around specific segments. This includes regional go-to-market models and placing R&D, product management, and sales back into the businesses for closer customer alignment.
Q:What is the company's perspective on the macroeconomic impact on CapEx and government shutdown?
A:The company noted a pause in projects with NIH and other entities due to the government shutdown, impacting Multiomics and SMS segments. They rely on real-time customer data to guide their outlook.
Q:What is the confidence in back-half acceleration and EPS expectations?
A:The company expects better performance in the second half due to investments in commercial operations and price optimization. EPS is expected to be better than $0.50, with a focus on margin expansion and EBITDA growth.
Q:What are the company's M&A priorities and expectations for 2026?
A:The company is focused on tuck-in acquisitions to expand core businesses in SRS, automated solutions, and synthesis. They view 2026 as a year for executing these plans after building a stable foundation in 2025.
Q:What are the expectations for Automated Stores and their contribution to growth?
A:Automated Stores are expected to grow in the low single digits, with investments in R&D expected to contribute to growth in 2027 and 2028. The company is focusing on attachment rates for consumables and services to drive growth.
Q:What is the market growth rate for Stores in Cryo and the company's strategy?
A:The market growth rate for Stores in Cryo is low single digits. The company aims to outgrow the market by capturing market share and increasing attachment rates for consumables and services.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about why EPS is flattish year-on-year despite a 300 basis point margin expansion. They emphasized EBITDA growth and valuation metrics instead of addressing the specific EPS dynamics.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABS discipline
ABS framework
Azenta discussion
Azenta journey
Azenta resilience
Azenta strength
Azenta system
Day phase
Decision making
Employees inefficiency
Friday conference
Relations course
Systems release
ability volatility
accountability agility
accountability improvement
accountability outcome
agility Decision
approach core
area Azenta
asset product
automation workflow
backdrop NIH
biopharma priority
breakthrough force
capital approach
capital share
challenge Azenta
change Azenta
change ground
commitment creation
company accountability
conference Friday
core margin
creation excellence
partner
place
productivity capital
start
uncertainty
AZTA Transcript
Azenta, Inc. (AZTA) Q2 2026 Earnings Call Transcript
Positive5-6
The company demonstrated strong financial performance with a 10% revenue increase, improved gross margins, and a significant rise in net income. The 20% boost in cash flow from operations indicates robust financial health. Despite potential risks from discontinued operations, the overall outlook is positive, supported by operational efficiencies and cost management. The market cap suggests a moderate reaction, leading to a 2% to 8% positive stock price movement.
Azenta, Inc. (AZTA) Q1 2026 Earnings Call Transcript
Positive2-4
The earnings call presents a positive outlook with strong financial metrics, optimistic guidance, and strategic growth initiatives. Despite some uncertainties in specific segments like Sanger, the overall sentiment is buoyed by successful bundling, regionalization efforts, and positive momentum in key markets. The company's focus on capital deployment and margin improvements further supports a positive stock price movement. Given the market cap, the stock is likely to experience a moderate positive reaction over the next two weeks.
Azenta, Inc. (AZTA) Q4 2025 Earnings Call Transcript
Unknown11-21
The earnings call presented mixed signals: strong cash flow improvement and record Multiomics revenue are positives, but declining gross margins and unclear EPS guidance are concerns. The Q&A highlighted growth challenges due to macroeconomic factors and government funding issues, yet management's optimism for H2 growth and strategic investments provide some reassurance. With a market cap of $2.8 billion, the stock's reaction is likely to be moderate, hence a neutral prediction.
Azenta, Inc. (AZTA) Q3 2025 Earnings Call Transcript
Unknown8-5
The earnings call presents mixed signals: strong SMS margin improvements and positive Q4 growth outlook are offset by declines in organic revenue and Multiomics margins. The Q&A reveals confidence in future guidance and no cancellations, but also highlights timing issues and lack of clarity on innovation pipeline contributions. The market cap suggests moderate stock reaction, supporting a neutral prediction.
AZTA Slides
AZTA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
